Tirzepatide Half-Life Explained:
Why Week 4 Feels Different.

If you're on Mounjaro or Zepbound — both tirzepatide — you've probably noticed something by the fourth or fifth week: appetite suppression is stronger than the dose would suggest. Week 1 feels like a nudge. Week 4 feels like a different drug. That's not titration psychology. It's math.

Tirzepatide has a half-life of roughly 5 days. On a weekly schedule, you're injecting the next dose before the previous one has decayed more than halfway. Doses stack. The active level in your bloodstream keeps climbing for about a month before the curve flattens out.

The one-line version

Your active tirzepatide level at steady state is about 2.5× your weekly dose — and it takes ~4–5 weeks to get there.

What "half-life" actually means

Half-life (t½) is the time it takes for the body to eliminate half of a drug's active amount. If you inject 5 mg of tirzepatide and its t½ is 5 days, then:

• Day 0: 5.0 mg active
• Day 5: 2.5 mg active (one half-life)
• Day 10: 1.25 mg active (two half-lives)
• Day 15: 0.62 mg active
• Day 20: 0.31 mg active

That's the decay from a single injection. But you're not injecting once. You're injecting every 7 days — and when dose 2 lands on day 7, there's still ~2.3 mg of dose 1 active. Dose 2 adds to that, not replaces it.

Stacking: the real story

Each new injection lands while the previous dose is still half-active. The faint dashed lines below are the individual decay tails from six weekly 2 mg doses with a 7-day half-life; the solid amber line is what your body actually sees at any moment — the sum of all those tails.

Here's what the active level looks like over five weeks of 5 mg weekly injections (approximate, assuming perfect sub-Q absorption):

By week 4, you have almost twice as much tirzepatide working in you as you had on week 1 — at the same weekly dose. That's why appetite suppression keeps getting stronger even though the number on your syringe hasn't changed.

Why dose escalation compounds this

The standard tirzepatide titration is 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, stepping up roughly every 4 weeks. Each step happens right around when the previous dose is reaching steady state.

So when you move from 2.5 mg to 5 mg, the first week on 5 mg doesn't feel like "5 mg worth of drug." It feels like 5 mg stacked on top of residual 2.5 mg, sliding toward a new steady state that's higher than what you just had. This is why dose-escalation weeks often bring nausea spikes — the active level is climbing faster than your receptors adapted to.

The Bateman equation

Protokol Lab models this with the Bateman equation — the standard two-compartment pharmacokinetic model for subcutaneous absorption:

C(t) = D · (kₐ / (kₐ − kₑ)) · (e^(−kₑ·t) − e^(−kₐ·t))

Where D is dose, kₐ is the absorption rate constant (~ln(2)/0.25 days for sub-Q tirzepatide, giving a 6-hour absorption rise), and kₑ is the elimination rate (ln(2) / 5 days for tirzepatide).

For multiple doses, you sum the contribution of each past dose at any current time t. That's what produces the stacked curve.

What this means for tracking

1. A "bad" week in month 1 isn't a bad dose. It's the absence of the stack. Your active level is lower than it will be at steady state — because you haven't built up a stack yet.
2. Steady state takes ~4–5 half-lives. For tirzepatide on weekly dosing, that's about 20–25 days. You don't know how a dose "really" works until week 4.
3. Skipped doses hit hard. Miss one and your active level halves by the time the next dose lands. Expect appetite to return and nausea to drop.
4. Dose-escalation nausea is real. It's not a bigger drug — it's a rising stack. If you need to, sit longer at a step before titrating up.

How Protokol Lab visualizes this

Every dose you log gets plotted on a pharmacokinetic curve — one line for each compound, stacked correctly so the "active now" number at the top of your dashboard reflects all doses from the past month, not just the last one.

Log a future dose to see where your active level will be next week. Skip a dose in the model and watch the curve drop. Compare a 5-mg weekly schedule against a 7.5-mg schedule to see the steady-state difference before committing.

References

• Urva S, et al. "Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide." Clinical Pharmacokinetics (2021).
• Coskun T, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus." Molecular Metabolism (2018).